109 related articles for article (PubMed ID: 24382084)
21. Clinical roundtable monograph: Paroxysmal nocturnal hemoglobinuria: a case-based discussion.
Szer J; Hill A; Weitz IC
Clin Adv Hematol Oncol; 2012 Nov; 10(11 Suppl 21):1-16. PubMed ID: 23271156
[TBL] [Abstract][Full Text] [Related]
22. Tocilizumab for treating refractory haemolytic anaemia in a patient with systemic lupus erythematosus.
García-Hernández FJ; González-León R; Castillo-Palma MJ; Ocaña-Medina C; Sánchez-Román J
Rheumatology (Oxford); 2012 Oct; 51(10):1918-9. PubMed ID: 22513150
[No Abstract] [Full Text] [Related]
23. Paroxysmal nocturnal hemoglobinuria and other complement-mediated hematological disorders.
Risitano AM
Immunobiology; 2012 Nov; 217(11):1080-7. PubMed ID: 22964233
[TBL] [Abstract][Full Text] [Related]
24. Improvement in the symptoms of smooth muscle dystonia during eculizumab therapy in paroxysmal nocturnal hemoglobinuria.
Hill A; Rother RP; Hillmen P
Haematologica; 2005 Dec; 90(12 Suppl):ECR40. PubMed ID: 16464755
[TBL] [Abstract][Full Text] [Related]
25. Eculizumab inhibits hemolysis in a model of ABO-incompatible red blood cell transfusion.
Fata CR; Gehrie EA; Young PP
Transfusion; 2015 Jul; 55(7):1823-4. PubMed ID: 26172150
[No Abstract] [Full Text] [Related]
26. Paroxysmal nocturnal hemoglobinuria.
Parker CJ
Curr Opin Hematol; 2012 May; 19(3):141-8. PubMed ID: 22395662
[TBL] [Abstract][Full Text] [Related]
27. [Afibrinogenemia and the Bernard-Soulier syndrome].
Dyerberg J; Jensen MK; Stoffersen E
Ugeskr Laeger; 1977 Jul; 139(29):1715-9. PubMed ID: 898353
[No Abstract] [Full Text] [Related]
28. Dramatic erythroid response to low-dose thalidomide in two patients with transfusion independent thalassemia and severe post-transfusional alloimmune hemolysis.
Fozza C; Pardini S; Giannico DB; Targhetta C; Di Tucci AA; Dessalvi P; Angelucci E; Dore F
Am J Hematol; 2015 Jul; 90(7):E141. PubMed ID: 25850682
[No Abstract] [Full Text] [Related]
29. Successful cholecystectomy in a patient with aplastic anemia-paroxysmal nocturnal hemoglobinuria during eculizumab treatment.
Ando K; Gotoh A; Yoshizawa S; Gotoh M; Iwabuchi T; Ito Y; Ohyashiki K
Ann Hematol; 2012 Dec; 91(12):1987-8. PubMed ID: 22739575
[No Abstract] [Full Text] [Related]
30. Recent advances in the diagnosis, monitoring, and management of patients with paroxysmal nocturnal hemoglobinuria.
Richards SJ; Hill A; Hillmen P
Cytometry B Clin Cytom; 2007 Sep; 72(5):291-8. PubMed ID: 17549742
[TBL] [Abstract][Full Text] [Related]
31. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria.
Hillmen P; Elebute M; Kelly R; Urbano-Ispizua A; Hill A; Rother RP; Khursigara G; Fu CL; Omine M; Browne P; Rosse W
Am J Hematol; 2010 Aug; 85(8):553-9. PubMed ID: 20658586
[TBL] [Abstract][Full Text] [Related]
32. Optic neuritis in CD59 deficiency: an extremely rare presentation.
Günay Ç; Yardım E; Yaşar E; Hız-Kurul AS; Uzan GS; Öztürk T; Yaman A; Yiş U
Turk J Pediatr; 2022; 64(4):787-794. PubMed ID: 36082655
[TBL] [Abstract][Full Text] [Related]
33. Eculizumab opens a new era of treatment for paroxysmal nocturnal hemoglobinuria.
Schrezenmeier H; Höchsmann B
Expert Rev Hematol; 2009 Feb; 2(1):7-16. PubMed ID: 21082989
[TBL] [Abstract][Full Text] [Related]
34. Recurrent Demyelinating Episodes as Sole Manifestation of Inherited CD59 Deficiency.
Solmaz I; Aytekin ES; Çağdaş D; Tan C; Tezcan I; Gocmen R; Haliloglu G; Anlar B
Neuropediatrics; 2020 Jun; 51(3):206-210. PubMed ID: 31752029
[TBL] [Abstract][Full Text] [Related]
35. Inherited CD59 deficiency, where neurology and genetics intertwine.
Almutawea LM; Hajeri AAA; Farid EM; Bushail MY; Ali AK
Neurosciences (Riyadh); 2023 Apr; 28(2):130-135. PubMed ID: 37045466
[TBL] [Abstract][Full Text] [Related]
36. Vitamin E--a radical defense.
Oski FA
N Engl J Med; 1980 Aug; 303(8):454-5. PubMed ID: 7393272
[No Abstract] [Full Text] [Related]
37. [Paroxysmal nocturnal hemoglobinuria (PNH). Pathogenesis, diagnosis and treatment].
Röth A; Dührsen U; Schrezenmeier H; Schubert J
Dtsch Med Wochenschr; 2009 Feb; 134(9):404-9. PubMed ID: 19224425
[TBL] [Abstract][Full Text] [Related]
38. Eculizumab: safety and efficacy after 17 months of treatment in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome: case report.
Châtelet V; Lobbedez T; Frémeaux-Bacchi V; Ficheux M; Ryckelynck JP; Hurault de Ligny B
Transplant Proc; 2010 Dec; 42(10):4353-5. PubMed ID: 21168697
[TBL] [Abstract][Full Text] [Related]
39. Gonococcal septic shock associated with eculizumab treatment.
Gleesing J; Chiwane S; Rongkavilit C
Pediatr Infect Dis J; 2012 May; 31(5):543. PubMed ID: 22511000
[No Abstract] [Full Text] [Related]
40. Hemolytic anemia and susceptibility to hydrogen-peroxide hemolysis in children with vitamin E-deficiency and chronic liver disease.
Fernández-Zamorano A; Arnalich F; Codoceo R; Vigara MR; Valverde F; Jara P; Vázquez JJ
J Med; 1988; 19(5-6):317-34. PubMed ID: 3204329
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
